Immuno-oncology Significant advancement has been made in the immuno-oncology portfolio since the pipeline update at Q1 results presentation on 24 April 2014, including:
First patient randomisation in the Phase III PACIFIC study, investigating the efficacy of MEDI4736 as a sequential therapy following chemoradiation in patients with locally advanced, unresectable NSCLC.
At the American Society of Clinical Oncology (ASCO) meeting, AstraZeneca announced the Phase III investment decision made to investigate the combination of PD-L1 and tremelimumab in 3rd line NSCLC patients to start in 2014. Subsequently, the Company has made the decision to initiate a pivotal programme for PD-L1 monotherapy as well as the combination with tremelimumab in head and neck cancer in 2014.
The ongoing randomised study with tremelimumab in unresectable pleural or peritoneal mesothelioma has been expanded for registrational intent.
Additional Phase I combination studies for MEDI4736 have been initiated, including combinations with Iressa and MEDI0680 (anti-PD-1 mAb). Other combination trials, including two Phase I studies in combination with AZD9291 are planned to start imminently.
The Company has also signed agreements to evaluate MEDI4736 in combination with Incyte’s IDO1 inhibitor, Kyowa Hakko Kirin’s anti-CCR4 antibody, mogamulizumab, and Advaxis’ lead cancer immunotherapy, ADXS-HPV.
European Society for Medical Oncology (ESMO) meeting, 26 – 30 September 2014 AstraZeneca has submitted numerous scientific abstracts across its oncology pipeline for presentation at the ESMO meeting in Madrid. The Company will also host a briefing for analysts and investors during the ESMO conference, with anticipated highlights: Further update on PD-L1 monotherapy Phase I study. Update on PD-L1/CTLA-4 combination in NSCLC to include: More patients, further dosing cohorts and PD-L1 biomarker status. Update on AZD9291 in NSCLC,
AstraZeneca PLC second quarter and half year results 201431 July 2014
The most crushing stat from a report out today by Public Health England is that, against a fanfare for new, improved, and in some cases near-“miracle” treatments, the number of those chronically infected with hepatitis C that ...
For people who don't already know, here's the difference between type 1 and type 2 diabetes: the body produces little or no insulin in the case of type 1, and isn't able to utilize the insulin that it does produce in type 2. It's a significant difference, so it's important that patients are diagnosed correctly. Thanks to a new microchip developed by a team at Stanford University led by Dr. Brian Feldman, doing so could soon be quicker, cheaper and easier than ever before.
In order to determine that a patient has type 1 diabetes as opposed to type 2, tests must be performed to confirm the presence of tell-tale antibodies in a sample of their blood. These tests must be performed by extensively-trained personnel in a lab, they involve the use of radioactive materials, take days to get results, and cost hundreds of dollars per test.
Because of these factors, the tests are sometimes not even performed, as it's generally assumed that children will get type 1 and adults will get type 2. In recent years, however, childhood obesity has caused a rise in the number of kids getting type 2, plus there's also a puzzling increase in adults with type 1.
That's where the Stanford chip comes in.
It can be incorporated into a hand-held device that could be used in the field with minimal training, delivering results in minutes. The chip doesn't require any radioactive material, is worth about $20, and can be used for about 15 tests before needing to be replaced. Additionally, it only requires a drop of blood, as opposed to the larger amount needed in the traditional system.
Sharing your scoops to your social media accounts is a must to distribute your curated content. Not only will it drive traffic and leads through your content, but it will help show your expertise with your followers.
How to integrate my topics' content to my website?
Integrating your curated content to your website or blog will allow you to increase your website visitors’ engagement, boost SEO and acquire new visitors. By redirecting your social media traffic to your website, Scoop.it will also help you generate more qualified traffic and leads from your curation work.
Distributing your curated content through a newsletter is a great way to nurture and engage your email subscribers will developing your traffic and visibility.
Creating engaging newsletters with your curated content is really easy.